Skip to content

Sleep, Hypertension, and Nocturia: a Multicomponent Approach for Comorbid Illnesses

Sleep, Hypertension, and Nocturia: a Multicomponent Approach for Comorbid Illnesses

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05419830
Acronym
SHyN
Enrollment
30
Registered
2022-06-15
Start date
2022-06-01
Completion date
2024-01-30
Last updated
2024-12-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension, Nocturia, Sleep Disturbance

Brief summary

In this study the investigators target three common and comorbid illnesses among older adults namely nocturia or waking at night to void, poor sleep and hypertension. The aim of this proposal is to test behavioral sleep intervention to improve sleep and nocturia vs switching the time of antihypertensive administration to improve nighttime and in turn daytime blood pressure control.

Detailed description

The investigators posit that a vicious cycle operates between nocturia, poor sleep, and nighttime hypertension (HTN). HTN act through the pressure-natriuresis mechanism that links sodium (Na) and BP homeostasis: periodic increases in BP drive compensatory renal excretion of Na (natriuresis) and water (diuresis) to reduce blood volume and BP. Normally, BP and natriuresis declines during sleep, decreasing nighttime urine volume (NUV). Elevated nighttime BP increases nocturnal natriuresis causing an increase in nighttime urine volume and hence, NP: the major etiologic factor for nocturia in the elderly. In a recently completed study (AG050892, PI:Tyagi), it was found that poor sleep blunts the normal nighttime rise in antidiuretic hormone-a potent Na conserving hormone, which leads to nocturnal natriuresis and, as a result, NP. Hence, our model incorporates the effects of poor sleep and nighttime HTN on natriuresis, NP, and nocturia. The investigators postulate that treatments targeted towards these etiologies will help break this vicious cycle. Traditionally, antihypertensive medications are dosed in the morning targeting daytime BP. However, some research suggests that nighttime BP best predicts risk for major cardiovascular events. Several clinical trials of bedtime dosing of BP medication-chronotherapy- show better nighttime BP control. However, no clinical studies have considered or tested chronotherapy as a treatment for nocturia. With respect to poor sleep, the investigators have shown that brief behavioral treatment of insomnia (BBTI) significantly improves not only sleep but also self-reported nocturia among the elderly. Therefore, the investigators envision a multicomponent approach with chronotherapy (bedtime dosing of certain antihypertensives) and behavioral sleep intervention (BBTI) to concurrently address the prevalent and chronic, mutually exacerbating conditions: nocturia, poor sleep, and HTN. The current proposal aims to collect pilot data for a definitive randomized clinical trial. In the proposed pilot study 30 community-dwelling older adults (aged \>65) who take at ≥1 daily non-diuretic antihypertensive medication, have a mean SBP \>135 mm Hg, and awaken ≥2 times nightly to void will be randomly assigned to one of the 3 groups of 10 participants each to 1) morning (am) HTN medication dosing, 2) BBTI with am HTN medication dosing, 3) nighttime non-diuretic HTN medication dosing (chronotherapy) for 6 weeks. At baseline and 6 weeks, participants will undergo 48-hour ambulatory BP monitoring, in-home sleep study, complete a 3-day bladder diary. This protocol will allow the investigators to accomplish following Aims: Aim1: To assess the feasibility and effect of chronotherapy and BBTI in older adults with multiple comorbidities: HTN and nocturia Hypothesis 1: Chronotherapy and BBTI will be (a) feasible treatment options among comorbid older adults, and (b) nocturia and nighttime urine volume, and (c) nighttime systolic blood pressure (SBP) will have a greater decrease in BBTI and chronotherapy groups than usual care. Aim 2: Assess safety and treatment compliance with chronotherapy. Hypothesis 2: The investigators will assess treatment compliance and also collect data on nocturnal lightheadedness and falls to begin to address the safety of HTN chronotherapy.

Interventions

BEHAVIORALBBTI

Participants randomized to BBTI will receive 45- to 60-minute individual intervention session followed by a 30-minute follow-up session 2 weeks later, and 20-minute telephone calls after 1 and 3 weeks. BBTI will focus on four behaviors that promote sleep and discussion of homeostatic and circadian mechanisms of human sleep regulation. These four interventions are simple to conceptualize and implement, and constitute the core of efficacious multi-modal behavioral treatments for insomnia.

OTHERPM antihypertensive dosing or Chronotherapy

participants will be asked to switch their conventional once daily non-diuretic antihypertensive to bedtime

OTHERAM antihypertensive dosing

participants will be asked to continue taking their antihypertensive medication within an hour of awakening

Sponsors

National Institute on Aging (NIA)
CollaboratorNIH
University of Pittsburgh
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
DOUBLE (Investigator, Outcomes Assessor)

Masking description

The randomization envelopes will be prepared by the study statistician. Randomization and the intervention BBTI will be completed by research nurse and PI and the outcome assessor will be blinded to randomization.

Intervention model description

In the proposed pilot study 30 community-dwelling older adults (aged \>65) who take at ≥1 daily non-diuretic antihypertensive medication, have a mean SBP \>135 mm Hg, and awaken ≥2 times nightly to void will be randomly assigned to one of the 3 groups of 10 participants each to 1) morning (am) HTN medication dosing, 2) BBTI with am HTN medication dosing, 3) nighttime non-diuretic HTN medication dosing (chronotherapy) for 6 weeks.

Eligibility

Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
No

Inclusion criteria

The study shall include: ambulatory and functionally-independent community-dwelling men and women aged 65+ years, with 1. nocturia ≥2/night, and 2. history of high blood pressure and receives one or more non-diuretic, once daily antihypertensive- angiotensin converting enzyme inhibitor (ACE-I), angiotensin receptor blocker (ARB), calcium channel blocker (CCB), beta blocker

Exclusion criteria

1. Unstable or acute medical or central nervous system conditions 2. Untreated, current, severe psychiatric condition 3. Untreated, current, severe overactive bladder syndrome 4. Post void residual \> 30ml 5. Montreal cognitive assessment (MOCA) \<26 6. Currently diagnosed and/or treated Obstructive Sleep Apnea, Restless Legs Syndrome, parasomnia 7. Congestive heart failure, by exam 8. Chronic kidney disease, stage III-V (eGFR\<60) 9. \>14 alcohol drinks per week 10. \>3 caffeinated drinks (\ 300mg) per day

Design outcomes

Primary

MeasureTime frameDescription
Change in Mean Sleep Time Systolic Blood Pressure Dip Pre- vs Post-interventionBaseline and at 6 weeksThe mean sleep time systolic blood pressure dip will be quantified by calculating the difference between daytime mean systolic pressure and nighttime mean systolic pressure expressed as a percentage of the day value for each participant across the 48-hour recording period comparing baseline and post-intervention

Secondary

MeasureTime frameDescription
Change in Nocturia Frequency Pre- vs Post-interventionBaseline and at 6 weekschange in nocturia frequency pre- vs post-intervention as determined by 3-day bladder diary completed at both time points
Change in Nocturnal Polyuira Index (NPi) Pre vs Post-interventionBaseline and at 6 weeksNPi is calculated using nighttime and daytime urine volumes as reported in 3-day bladder diary as follows: NPi=(nocturnal urine volume/24-hour volume)\*100
Change in Global Pittsburgh Sleep Quality Index (PSQI) Score Pre- vs Post-interventionBaseline and at 6 weeksPSQI is a self-rated questionnaire for evaluating subjective sleep quality. PSQI global scores range from 0-21, with higher scores indicating worse sleep quality and negative change indicates sleep improvement.
Change in Sleep Efficiency Pre- vs Post-interventionBaseline and at 6 weeksSleep efficiency will be calculated as (total sleep time/time in bed)\*100 with time in bed and total sleep times obtained from Zmachine worn by participants pre- and post-intervention

Countries

United States

Participant flow

Recruitment details

Recruitment started June 2022 through September 2023. The initial screening was completed telephonically and once screened eligible, the interested participants underwent study related assessments and procedures at the study research suite - Continence Research Unit at University of Pittsburgh Medical Center, Montefiore Hospital located in Pittsburgh, Pennsylvania

Pre-assignment details

After the telephone screening, eligible participants were scheduled for the first in-person study visit. No study procedures were performed till informed consent was obtained.

Participants by arm

ArmCount
AM Antihypertensive Dosing Arm
participants will be asked to continue taking their antihypertensive medication within an hour of awakening AM antihypertensive dosing: participants will be asked to continue taking their antihypertensive medication within an hour of awakening
10
BBTI Arm
participants will receive the behavioral treatment for insomnia BBTI by the study RN. Participants will also be asked to take their antihypertensive medication within an hour of awakening BBTI: Participants randomized to BBTI will receive 45- to 60-minute individual intervention session followed by a 30-minute follow-up session 2 weeks later, and 20-minute telephone calls after 1 and 3 weeks. BBTI will focus on four behaviors that promote sleep and discussion of homeostatic and circadian mechanisms of human sleep regulation. These four interventions are simple to conceptualize and implement, and constitute the core of efficacious multi-modal behavioral treatments for insomnia.
10
PM Antihypertensive Dosing or Chronotherapy Arm
participants will be asked to switch their conventional once daily non-diuretic antihypertensive to bedtime PM antihypertensive dosing or Chronotherapy: participants will be asked to switch their conventional once daily non-diuretic antihypertensive to bedtime
10
Total30

Baseline characteristics

CharacteristicTotalAM Antihypertensive Dosing ArmBBTI ArmPM Antihypertensive Dosing or Chronotherapy Arm
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
30 Participants10 Participants10 Participants10 Participants
Age, Categorical
Between 18 and 65 years
0 Participants0 Participants0 Participants0 Participants
Age, Continuous71.6 years
STANDARD_DEVIATION 4.8
73.9 years
STANDARD_DEVIATION 5
69.4 years
STANDARD_DEVIATION 4.6
71.5 years
STANDARD_DEVIATION 4.2
Alpha- blocker4 Participants2 Participants1 Participants1 Participants
Angiotensin converting enzyme inhibitor/ Angiotensin receptor blocker24 Participants8 Participants9 Participants7 Participants
Antidepressant8 Participants1 Participants4 Participants3 Participants
Antimuscarinic1 Participants0 Participants1 Participants0 Participants
Beta-blocker9 Participants3 Participants5 Participants1 Participants
Body mass index (BMI)32.2 kg/m2
STANDARD_DEVIATION 6.4
31.2 kg/m2
STANDARD_DEVIATION 2.8
34 kg/m2
STANDARD_DEVIATION 8.7
31.4 kg/m2
STANDARD_DEVIATION 6.5
Calcium channel blocker13 Participants6 Participants3 Participants4 Participants
Hypnotic4 Participants0 Participants4 Participants0 Participants
Insulin1 Participants0 Participants1 Participants0 Participants
Loop diuretic2 Participants1 Participants1 Participants0 Participants
Nonsteroidal anti-inflammatory drugs (NSAIDs)2 Participants0 Participants0 Participants2 Participants
Office diastolic blood pressure82 mm Hg
STANDARD_DEVIATION 10.5
80.4 mm Hg
STANDARD_DEVIATION 8.3
79.9 mm Hg
STANDARD_DEVIATION 11
85.7 mm Hg
STANDARD_DEVIATION 11.7
Office heart rate66.2 beats per minute
STANDARD_DEVIATION 10.4
66.5 beats per minute
STANDARD_DEVIATION 13.4
63.6 beats per minute
STANDARD_DEVIATION 8.7
68.5 beats per minute
STANDARD_DEVIATION 8.9
Office systolic blood pressure145.8 mm Hg
STANDARD_DEVIATION 12.5
144.9 mm Hg
STANDARD_DEVIATION 13.3
137.4 mm Hg
STANDARD_DEVIATION 9.5
155.5 mm Hg
STANDARD_DEVIATION 14.6
oral hypoglycemic11 Participants3 Participants5 Participants3 Participants
Post void residual35.4 ml
STANDARD_DEVIATION 63.1
47 ml
STANDARD_DEVIATION 75.3
15.7 ml
STANDARD_DEVIATION 11.4
18.7 ml
STANDARD_DEVIATION 35
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Black or African American
4 Participants1 Participants3 Participants0 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
26 Participants9 Participants7 Participants10 Participants
Region of Enrollment
United States
30 participants10 participants10 participants10 participants
Sex: Female, Male
Female
17 Participants4 Participants7 Participants6 Participants
Sex: Female, Male
Male
13 Participants6 Participants3 Participants4 Participants
Statin19 Participants9 Participants4 Participants6 Participants
Thiazide diuretic10 Participants2 Participants3 Participants5 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
deaths
Total, all-cause mortality
0 / 100 / 100 / 10
other
Total, other adverse events
0 / 100 / 100 / 10
serious
Total, serious adverse events
0 / 100 / 100 / 10

Outcome results

Primary

Change in Mean Sleep Time Systolic Blood Pressure Dip Pre- vs Post-intervention

The mean sleep time systolic blood pressure dip will be quantified by calculating the difference between daytime mean systolic pressure and nighttime mean systolic pressure expressed as a percentage of the day value for each participant across the 48-hour recording period comparing baseline and post-intervention

Time frame: Baseline and at 6 weeks

ArmMeasureValue (MEAN)Dispersion
AM Antihypertensive Dosing ArmChange in Mean Sleep Time Systolic Blood Pressure Dip Pre- vs Post-intervention-0.4 percentage of daytime mean SBPStandard Deviation 7.9
BBTI ArmChange in Mean Sleep Time Systolic Blood Pressure Dip Pre- vs Post-intervention7.3 percentage of daytime mean SBPStandard Deviation 13.5
PM Antihypertensive Dosing or Chronotherapy ArmChange in Mean Sleep Time Systolic Blood Pressure Dip Pre- vs Post-intervention3.9 percentage of daytime mean SBPStandard Deviation 10
p-value: 0.65ANCOVA
Secondary

Change in Global Pittsburgh Sleep Quality Index (PSQI) Score Pre- vs Post-intervention

PSQI is a self-rated questionnaire for evaluating subjective sleep quality. PSQI global scores range from 0-21, with higher scores indicating worse sleep quality and negative change indicates sleep improvement.

Time frame: Baseline and at 6 weeks

ArmMeasureValue (MEAN)Dispersion
AM Antihypertensive Dosing ArmChange in Global Pittsburgh Sleep Quality Index (PSQI) Score Pre- vs Post-intervention0.5 score on a scaleStandard Deviation 2.9
BBTI ArmChange in Global Pittsburgh Sleep Quality Index (PSQI) Score Pre- vs Post-intervention-1.4 score on a scaleStandard Deviation 2.2
PM Antihypertensive Dosing or Chronotherapy ArmChange in Global Pittsburgh Sleep Quality Index (PSQI) Score Pre- vs Post-intervention-1.2 score on a scaleStandard Deviation 3.7
p-value: 0.2ANCOVA
Secondary

Change in Nocturia Frequency Pre- vs Post-intervention

change in nocturia frequency pre- vs post-intervention as determined by 3-day bladder diary completed at both time points

Time frame: Baseline and at 6 weeks

ArmMeasureValue (MEAN)Dispersion
AM Antihypertensive Dosing ArmChange in Nocturia Frequency Pre- vs Post-intervention-0.3 number of episodesStandard Deviation 1
BBTI ArmChange in Nocturia Frequency Pre- vs Post-intervention-0.6 number of episodesStandard Deviation 0.7
PM Antihypertensive Dosing or Chronotherapy ArmChange in Nocturia Frequency Pre- vs Post-intervention-0.3 number of episodesStandard Deviation 0.8
p-value: 0.66ANCOVA
Secondary

Change in Nocturnal Polyuira Index (NPi) Pre vs Post-intervention

NPi is calculated using nighttime and daytime urine volumes as reported in 3-day bladder diary as follows: NPi=(nocturnal urine volume/24-hour volume)\*100

Time frame: Baseline and at 6 weeks

ArmMeasureValue (MEAN)Dispersion
AM Antihypertensive Dosing ArmChange in Nocturnal Polyuira Index (NPi) Pre vs Post-intervention0.5 % of 24h urine output excreted at nightStandard Deviation 7.4
BBTI ArmChange in Nocturnal Polyuira Index (NPi) Pre vs Post-intervention-6.0 % of 24h urine output excreted at nightStandard Deviation 9.7
PM Antihypertensive Dosing or Chronotherapy ArmChange in Nocturnal Polyuira Index (NPi) Pre vs Post-intervention-0.9 % of 24h urine output excreted at nightStandard Deviation 7.6
p-value: 0.14ANCOVA
Secondary

Change in Sleep Efficiency Pre- vs Post-intervention

Sleep efficiency will be calculated as (total sleep time/time in bed)\*100 with time in bed and total sleep times obtained from Zmachine worn by participants pre- and post-intervention

Time frame: Baseline and at 6 weeks

ArmMeasureValue (MEAN)Dispersion
AM Antihypertensive Dosing ArmChange in Sleep Efficiency Pre- vs Post-intervention-7 %: (total sleep time/time in bed)*100Standard Deviation 15.3
BBTI ArmChange in Sleep Efficiency Pre- vs Post-intervention12 %: (total sleep time/time in bed)*100Standard Deviation 7.8
PM Antihypertensive Dosing or Chronotherapy ArmChange in Sleep Efficiency Pre- vs Post-intervention-3 %: (total sleep time/time in bed)*100Standard Deviation 11.8
p-value: 0.02ANCOVA

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026